Amber and her family in the Volkswagen convertible she bought after learning she was cancer-free Amber used to live her life with anxiety and fear—always trying to stay within her comfort zone. She ...

They were given little hope of survival after being diagnosed with cancer, but now thanks to a little-known procedure they are continuing on with their lives. Kelly McCarley of Owings and Joe Finn of ...

Ovarian cancer often goes undetected until it spreads to other areas. In its late stages, it's harder to treat. Now there's an unconventional treatment being used to get rid of it. When her stomach ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer. Among patients with platinum-sensitive peritoneal ...

Median progression-free survival (PFS) improved from 23 months with surgery alone to 25 months with the addition of hyperthermic intraperitoneal chemotherapy (HIPEC), a nonsignificant difference. Post ...

Tamron Little, diagnosed with peritoneal mesothelioma during pregnancy, underwent HIPEC surgery and has survived 18 years beyond her initial prognosis. She emphasizes the importance of mental health ...

A single-center, open-label, single-arm, phase I study with dose expansion cohort of sacituzumab govitecan in combination with cisplatin for patients with platinum sensitive recurrent ovarian and ...

A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC). This is an ASCO ...